Aberdeen life sciences firm Elasmogen nets six-figure funding boost

A spin-out from the University of Aberdeen that describes itself as a drug discovery pioneer has won two six-figure grants totalling £374,000 to support programs for Covid-19 and oncology.
The firm highlights the 'world-class' drug discovery effort going on in Aberdeen. Picture: Lewis J Houghton.The firm highlights the 'world-class' drug discovery effort going on in Aberdeen. Picture: Lewis J Houghton.
The firm highlights the 'world-class' drug discovery effort going on in Aberdeen. Picture: Lewis J Houghton.

Elasmogen in April secured £143,000 from the Scottish Government to use its drug discovery platform to accelerate the development of new diagnostics and therapeutics for Covid-19, a joint undertaking with the University of Aberdeen’s Scottish Biologics Facility. This key grant facilitated the re-opening of the company’s laboratories.

Chief executive Caroline Barelle said: “We were caught up in the university buildings’ closures, and so all work in our labs stopped at the end of March. The timing of the lockdown was incredibly frustrating as our data was beginning to show such exciting promise. Everything changed in late April with the success of our Covid-19 funding, which allowed us to not only help in the fight against this pandemic – but meant we could open up our labs again.

Read More
Aberdeen university spin-out gets £2m cash injection to develop cancer treatment
Elasmogen highlights 20-plus patents granted globally. Picture: contributed.Elasmogen highlights 20-plus patents granted globally. Picture: contributed.
Elasmogen highlights 20-plus patents granted globally. Picture: contributed.
Hide Ad
Hide Ad

“Our Covid-19 work is progressing very well and we already have a panel of a new class of binders to the business end of the virus, the spike protein.” Barelle added that these new molecules will be developed with others into sensitive and rapid diagnostics – like a “pregnancy test” but for Covid-19 – as well as new therapeutics to fight the disease.

The second award is a UK Research and Innovation Continuity Grant of £231,000 providing additional support for Elasmogen’s joint undertaking with Almac Discovery and its labs in Edinburgh and Northern Ireland.

Almac synthesises cancer-killing chemical “warheads” that are combined with Elasmogen’s cancer-seeking capabilities, originating in the immune system of sharks, to more effectively destroy hard-to-treat solid tumours.

Barelle said: “Whilst the fight against Covid-19 is happening now, the fight against cancer will continue long after Covid-19 is under control; and so it is wonderful that we can now use this innovate funding to bring the rest of the team back on site and continue our cancer programs.”

“The team have worked so hard to achieve these successes out of what could have been a company-ending break. Everyone knows Aberdeen as the oil and gas city but often forget that there is a world-class drug discovery effort going on in companies across the city too.”

Stephen Logan of Opportunity North East, stated: “Elasmogen is one of the region’s high-growth life sciences companies specialising in developing novel biotherapeutics. The action and investment by ONE and partners in the life sciences cluster in Aberdeen to accelerate collaborative innovation and commercialisation will help to anchor companies like Elasmogen in the region long term.”

A message from the Editor:

Thank you for reading this story on our website. While I have your attention, I also have an important request to make of you.

The dramatic events of 2020 are having a major impact on many of our advertisers - and consequently the revenue we receive. We are now more reliant than ever on you taking out a digital subscription to support our journalism.

Hide Ad
Hide Ad

Subscribe to scotsman.com and enjoy unlimited access to Scottish news and information online and on our app. Visit https://www.scotsman.com/subscriptions now to sign up.

By supporting us, we are able to support you in providing trusted, fact-checked content for this website.

Joy Yates

Editorial Director



Want to join the conversation? Please or to comment on this article.